Test drug azenosertib for platinum-resistant ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests azenosertib to treat platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. It looks for whether the drug can shrink tumors and improve outcomes in people whose cancer has returned after platinum chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old
- Have high-grade serous ovarian, fallopian tube, or primary peritoneal cancer (not endometrioid/clear cell/mucinous/low-grade/borderline)
- Your tumor must test positive for “Cyclin E1” using the study’s required lab test (archived tumor tissue is allowed)
- Your cancer must be “platinum-resistant,” meaning it did not respond well to prior platinum chemotherapy
- You must have had required prior treatments: bevacizumab (if standard for you) and, if applicable, a PARP inhibitor (for BRCA1/2 or HRD) and mirvetuximab (if standard for you)
- You must be well enough for treatment: ECOG 0–1 and blood/organ tests must be adequate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill called INCB123667 for people with a type of ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called azenosertib against standard chemotherapy for ovarian, fallopian tube, or peritoneal cancer that has come back after platinum-based treatment. The drug targets a specific protein (cyclin E1) found in some tumors and may help stop cancer cells from dividing.
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
This trial is testing an oral drug called azenosertib for a type of uterine cancer that has come back or spread. It aims to see if blocking a DNA repair pathway can shrink tumors or slow their growth.
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
Hear when a new High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.